open access

Vol 93, No 4 (2022)
Review paper
Early publication date: 2022-02-04
Get Citation

Sentinel lymph node mapping in endometrial cancer after 2020 ESGO-ESTRO-ESP consensus update: what will happen in the next few years?

Bartlomiej Barczynski1, Karolina Fraszczak1, Wieslawa Bednarek1
DOI: 10.5603/GP.a2021.0214
·
Pubmed: 35156700
·
Ginekol Pol 2022;93(4):321-328.
Affiliations
  1. Medical University in Lublin, Poland, Poland

open access

Vol 93, No 4 (2022)
REVIEW PAPERS Gynecology
Early publication date: 2022-02-04

Abstract

Comprehensive endometrial cancer staging requires mandatory lymph node status assessment. However, some randomized clinical studies show that full lymphadenectomy may have no therapeutic benefit in patients presented with early-stage disease. Sentinel lymph node mapping can be considered in patients at low to intermediate risk for nodal metastases and is an acceptable alternative to systemic lymphadenectomy for lymph node staging in FIGO stage I/II patients. Similarly, patients with serious comorbidities who might not tolerate a standard systemic lymphadenectomy may benefit from the procedure. Sentinel lymph node detection rates depend on cancer stage, histology, and technique used. The procedure is most performed with the use of radioactive technetium colloid (99mTc) combined with a blue dye or indocyanine green. Recently, more interest is also paid to new nanoparticles including carbon, superparamagnetic iron oxide, and mannose tracer agents. Growing interest in sentinel lymph node mapping technique has led to design increasing number of research projects regarding various mapping approaches in different endometrial cancer populations. Much attention has been paid to a non-invasive sentinel lymph node mapping technique e.g., radiomics. This article reviews the latest research on sentinel lymph node mapping perspectives in endometrial cancer patients.

Abstract

Comprehensive endometrial cancer staging requires mandatory lymph node status assessment. However, some randomized clinical studies show that full lymphadenectomy may have no therapeutic benefit in patients presented with early-stage disease. Sentinel lymph node mapping can be considered in patients at low to intermediate risk for nodal metastases and is an acceptable alternative to systemic lymphadenectomy for lymph node staging in FIGO stage I/II patients. Similarly, patients with serious comorbidities who might not tolerate a standard systemic lymphadenectomy may benefit from the procedure. Sentinel lymph node detection rates depend on cancer stage, histology, and technique used. The procedure is most performed with the use of radioactive technetium colloid (99mTc) combined with a blue dye or indocyanine green. Recently, more interest is also paid to new nanoparticles including carbon, superparamagnetic iron oxide, and mannose tracer agents. Growing interest in sentinel lymph node mapping technique has led to design increasing number of research projects regarding various mapping approaches in different endometrial cancer populations. Much attention has been paid to a non-invasive sentinel lymph node mapping technique e.g., radiomics. This article reviews the latest research on sentinel lymph node mapping perspectives in endometrial cancer patients.

Get Citation

Keywords

endometrial cancer; sentinel lymph node; indocyanine green

About this article
Title

Sentinel lymph node mapping in endometrial cancer after 2020 ESGO-ESTRO-ESP consensus update: what will happen in the next few years?

Journal

Ginekologia Polska

Issue

Vol 93, No 4 (2022)

Article type

Review paper

Pages

321-328

Early publication date

2022-02-04

Page views

410

Article views/downloads

176

DOI

10.5603/GP.a2021.0214

Pubmed

35156700

Bibliographic record

Ginekol Pol 2022;93(4):321-328.

Keywords

endometrial cancer
sentinel lymph node
indocyanine green

Authors

Bartlomiej Barczynski
Karolina Fraszczak
Wieslawa Bednarek

References (42)
  1. Kitchener H, Swart AMC, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125–136.
  2. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707–1716.
  3. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
  4. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine neoplasms. Version 1.2021 – October 20, 2020. https://www.nccn.org/professionals/physician_gls/default.aspx#uterine (15.05.2021).
  6. Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017; 146(2): 405–415.
  7. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017; 146(2): 234–239.
  8. Bogani G, Martinelli F, Ditto A, et al. Sentinel lymph node detection in endometrial cancer: does injection site make a difference? J Gynecol Oncol. 2016; 27(2): e23.
  9. Buda A, Crivellaro C, Elisei F, et al. Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99m)tc and/or blue dye. Ann Surg Oncol. 2016; 23(7): 2183–2191.
  10. Papadia A, Gasparri ML, Buda A, et al. Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue. J Cancer Res Clin Oncol. 2017; 143(10): 2039–2048.
  11. Zuo J, Wu LY, Cheng M, et al. Comparison study of laparoscopic sentinel lymph node mapping in endometrial carcinoma using carbon nanoparticles and lymphatic pathway verification. J Minim Invasive Gynecol. 2019; 26(6): 1125–1132.
  12. Taruno K, Kurita T, Kuwahata A, et al. Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe. J Surg Oncol. 2019; 120(8): 1391–1396.
  13. Wallace AM, Hoh CK, Ellner SJ, et al. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007; 14(2): 913–921.
  14. Azad AK, Rajaram MVS, Metz WL, et al. γ-Tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). J Immunol. 2015; 195(5): 2019–2029.
  15. Stephens AJ, Kennard JA, Fitzsimmons CK, et al. Robotic sentinel lymph node (SLN) mapping in endometrial cancer: SLN symmetry and implications of mapping failure. Int J Gynecol Cancer. 2020; 30(3): 305–310.
  16. Tortorella L, Casarin J, Multinu F, et al. Sentinel lymph node biopsy with cervical injection of indocyanine green in apparent early-stage endometrial cancer: predictors of unsuccessful mapping. Gynecol Oncol. 2019; 155(1): 34–38.
  17. Ye L, Li S, Lu W, et al. A prospective study of sentinel lymph node mapping for endometrial cancer: is it effective in high-risk subtypes? Oncologist. 2019; 24(12): e1381–e1387.
  18. Peiretti M, Candotti G, Buda A, et al. Feasibility of hand-assisted laparoscopic sentinel node biopsy in open endometrial cancer surgery. Minim Invasive Ther Allied Technol. 2020; 29(5): 299–303.
  19. Persson J, Salehi S, Bollino M, et al. Pelvic sentinel lymph node detection in high-risk endometrial cancer (shrec-trial) — the final step towards a paradigm shift in surgical staging. Eur J Cancer. 2019; 116: 77–85.
  20. Wang T, Hu Y, He Ya, et al. A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Arch Gynecol Obstet. 2019; 299(5): 1429–1435.
  21. Zuo J, Wu LY, Cheng M, et al. Comparison Study of Laparoscopic Sentinel Lymph Node Mapping in Endometrial Carcinoma Using Carbon Nanoparticles and Lymphatic Pathway Verification. J Minim Invasive Gynecol. 2019; 26(6): 1125–1132.
  22. Rossi E, Kowalski L, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. The Lancet Oncology. 2017; 18(3): 384–392.
  23. Rozenholc A, Samouelian V, Warkus T, et al. Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2019; 153(3): 500–504.
  24. Ianieri MM, Puppo A, Novelli A, et al. Sentinel lymph node biopsy in the treatment of endometrial cancer: why we fail? Results of a prospective multicenter study on the factors associated with failure of node mapping with indocyanine green. Gynecol Obstet Invest. 2019; 84(4): 383–389.
  25. Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. Int J Gynecol Cancer. 2008; 18(6): 1163–1168.
  26. Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol. 2009; 113(2): 163–169.
  27. Tanner EJ, Sinno AK, Stone RL, et al. Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. Gynecol Oncol. 2015; 138(3): 542–547.
  28. Sozzi G, Uccella S, Berretta R, et al. Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study. Int J Gynecol Cancer. 2018; 28(4): 684–691.
  29. Liu J, Sun D, Chen L, et al. Radiomics analysis of dynamic contrast-enhanced magnetic resonance imaging for the prediction of sentinel lymph node metastasis in breast cancer. Front Oncol. 2019; 9: 980.
  30. Liu C, Ding J, Spuhler K, et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer by radiomic signatures from dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2019; 49(1): 131–140.
  31. Crivellaro C, Landoni C, Elisei F, et al. Combining positron emission tomography/computed tomography, radiomics, and sentinel lymph node mapping for nodal staging of endometrial cancer patients. Int J Gynecol Cancer. 2020; 30(3): 378–382.
  32. Thompson JF, Haydu LE, Uren RF, et al. MSLT-II Trial Group. Preoperative ultrasound assessment of regional lymph nodes in melanoma patients does not provide reliable nodal staging: results from a large multicenter trial. Ann Surg. 2021; 273(4): 814–820.
  33. Tanaka T, Kamata M, Fukaya S, et al. Usefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer: does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma? J Eur Acad Dermatol Venereol. 2020; 34(4): 754–761.
  34. Nam K, Stapp R, Liu JB, et al. Performance of molecular lymphosonography for detection and quantification of metastatic involvement in sentinel lymph nodes. J Ultrasound Med. 2019; 38(8): 2103–2110.
  35. Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
  36. Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol. 2016; 143(1): 46–53.
  37. Imboden S, Mereu L, Siegenthaler F, et al. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection. Eur J Surg Oncol. 2019; 45(9): 1638–1643.
  38. Accorsi GS, Paiva LL, Schmidt R, et al. Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer: surgical morbidity and lymphatic complications. J Minim Invasive Gynecol. 2020; 27(4): 938–945.e2.
  39. Casarin J, Multinu F, Tortorella L, et al. Sentinel lymph node biopsy for robotic-assisted endometrial cancer staging: further improvement of perioperative outcomes. Int J Gynecol Cancer. 2020; 30(1): 41–47.
  40. Mathevet P, Lécuru F, Uzan C, et al. Senticol 2 group. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). Eur J Cancer. 2021; 148: 307–315.
  41. Januszek SM, Barnas E, Skret-Magierlo J, et al. Obesity as a risk factor of in-hospital outcomes in patients with endometrial cancer treated with laparoscopic surgical mode. Ginekol Pol. 2020; 91(10): 573–581.
  42. Wrobel A, Winkler I, Rechberger T, et al. Does intraoperative application of TachoSil reduce the number of lymphoceles after pelvic lymphadenectomy? Ginekol Pol. 2021 [Epub ahead of print].

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl